PBAC's latest decision on Rotavirus vaccine, live, oral liquid, pentavalent: Recommended (2006). Considered for Vaccination of all infants at 2, 4 and 6 months of age to prevent rotavirus gastroenteritis.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
$15k/QALY
$15k/QALY–— · across 2 submissions
Submissions
2
first 2006
Submissions
2
2006 → 2006
Eligible population
Infants at 2, 4 and 6 months of age
Therapy area
Immunology
Evidence base
Registry | Other (systematic reviews)
Comparator
standard medical management without rotavirus vaccination
Economic model
CUA
Budget impact
$30M
ICER note
Revised ICER excluding work loss costs was <$15,000 per QALY gained; original submission was $45,000–$75,000
ICER basis
Range aggregates 2 submissions (2006) — not a single base case.
Submission history
2006: Not recommended — ICER $75k/QALY
Nov 2006: Recommended · Unrestricted — ICER $15k/QALY